This site is intended for healthcare professionals
Biosimilars in retinal disease Learning Zone

Biosimilars in retinal disease

Read time: 90 mins
Last updated:28th Jul 2022
Published:28th Jul 2022

Now that biosimilars are becoming available for retinal disease, how do they fit into management?

  • Learn about the development and approval process for biosimilars, and how they differ from generic medicines
  • Explore the evidence which supported regulatory approval for the first anti-VEGF biosimilar for retinal disease in Europe and the US
  • Discover how biosimilars may help to improve access to treatment for retinal disease, by helping to address the financial barriers to biologic treatment

Since the first biosimilar was approved by the European Medicines Agency (EMA) in 2006, over 16 years of clinical experience have been gained with understanding the efficacy and safety profile of these medicines1,2

Listen to Dr Ashish Sharma, an ophthalmologist at Lotus Eye Hospital and Institute in India, as he explains more about biosimilars, and whether they can be relied upon to achieve positive treatment outcomes for patients with retinal disease.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Listen to Dr Ashish Sharma, ophthalmologist at Lotus Eye Hospital and Institute in India, as he discusses the comprehensive approach to biosimilar development and approval in the US and Europe, and why biosimilars have only recently become available for treatment of retinal diseases.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Are biosimilars effective and safe for retinal disease?

Join Dr Ashish Sharma, an ophthalmologist at Lotus Eye Hospital and Institute in India, as he explores the evidence for efficacy of the first Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved biosimilar for retinal disease, ByoovizTM (ranibizumab-nuna), compared with reference ranibizumab (LucentisTM).

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Can biosimilars improve access to care?

Listen to Dr Ashish Sharma, an ophthalmologist at Lotus Eye Hospital and Institute in India, as he describes how biosimilars can facilitate improved access to treatment for patients with retinal disease, and the consequences of delayed treatment.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Integrating biosimilars into management of retinal disease

Dr Ashish Sharma, an ophthalmologist at Lotus Eye Hospital and Institute in India, describes some key considerations when switching between a reference medicine and a biosimilar, and considerations when discussing biosimilars with patients.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

  1. Gherghescu I, Delgado-Charro MB. The biosimilar landscape: An overview of regulatory approvals by the EMA and FDA. Pharmaceutics. 2021;13(1):1-16.
  2. European Medicines Agency and the European Commission. Biosimilars in the EU - Information guide for healthcare professionals. 2019. Available at: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 19 April 2022.
  3. US Food and Drug Administration. Biosimilar product regulatory review and approval. Available at: https://www.fda.gov/media/108621/download. Accessed 19 April 2022.
  4. Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. British Journal of Ophthalmology. 2020;104(1):2-7.
  5. Cardinal Health. 2022 Biosimilars report: the US journey and path ahead. 2022. Available at: https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-2022-biosimilars-report.pdf.
  6. Dutta B, Huys I, Vulto AG, Simoens S. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! Biodrugs. 2020;34(2):159-170.
  7. Kapur M, Nirula S, Naik MP. Future of anti-VEGF: biosimilars and biobetters. International Journal of Retina and Vitreous. 2022;8(1):2.
  8. Hariprasad SM, Gale RP, Weng CY, Ebbers HC, Rezk MF, Tadayoni R. An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. Ophthalmology and Therapy. 2022.
  9. US Food and Drug Administration. Biosimilar and interchangeable products. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products. Accessed 19 April 2022.
  10. Pfizer Inc. Biosimilar development. https://www.pfizerbiosimilars.com/biosimilars-development. Accessed 6 January 2020.
  11. Park JP, Jung B, Park HK, Shin D, Jung JA, Ghil J, et al. Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One. Biodrugs. 2022.
  12. Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye. 2019;33(9):1359-1361.
  13. Hagen T. Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology. https://www.centerforbiosimilars.com/view/review-biobetters-and-biosimilars-set-to-emerge-in-ophthalmology. Accessed 13 May 2022.
  14. US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 19 April 2022.
  15. European Medicines Agency. Centrally authorised biosimilar medicines. 2022. Available at: https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/
    ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_
    api_aggregation_ema_medicine_types/field_ema_med_biosimilar
    .
  16. Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs. 2021;81(16):1881-1896.
  17. US Food and Drug Administration. Nonproprietary naming of biological products: Guidance for industry. 2017. Available at: https://www.fda.gov/media/93218/download. Accessed 20 April 2022.
  18. Jordan JB, Christl L. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars? Expert Opinion on Drug Safety. 2020;19(3):229-232.
  19. US Food and Drug Administration. Nonproprietary naming of biological products: Update guidance for industry. 2019. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonproprietary-naming-biological-products-update-guidance-industry. Accessed 20 April 2022.
  20. Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, et al. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2021;139(1):68-76.
  21. Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studnička J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2021.
  22. European Medicines Agency. Byooviz. https://www.ema.europa.eu/en/medicines/human/EPAR/byooviz. Accessed 12 May 2022.
  23. US Food and Drug Administration. Biologics License Application - Approval Letter. 17 September 2021 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761202Orig1s000ltr.pdf.
  24. Harston A. How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline. https://www.biosimilarsip.com/2021/11/15/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-7/. Accessed 16 May 2022.
  25. Samsung Bioepis Co Ltd and Biogen Inc. BYOOVIZ (ranibizumab-nuna) - Full Prescribing Information (US). Last revised September 2021: US Food and Drug Administration; 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761202s000lbl.pdf. Accessed 12 May 2022.
  26. European Medicines Agency. BYOOVIZ EPAR Summary of Product Characteristics. EMA Last updated April 2022 2021. Available at: https://www.ema.europa.eu/en/documents/product-information/byooviz-epar-product-information_en.pdf.
  27. European Medicines Agency. EMA medicines search. https://www.ema.europa.eu/en/medicines. Accessed 27 May 2022.
  28. Biogen, 2021. FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) [press release].Available at: https://investors.biogen.com/news-releases/news-release-details/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11. Accessed 10 May 2022.
  29. The Center for Biosimilars. Ranibizumab Biosimilar (Byooviz) Gains EU Marketing Authorization. https://www.centerforbiosimilars.com/view/samsung-bioepis-byooviz-gains-ema-marketing-authorization. Accessed 12 May 2022.
  30. Chakraborty D, Stewart MW, Sheth JU, Sinha TK, Boral S, Das A, et al. Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases. Ophthalmol Ther. 2021;10(2):337-348.
  31. Sharma S, RE-ENACT Study Investigators Group, Khan M, Chaturvedi A. Real-Life Clinical Effectiveness of Razumab^® (World's First Biosimilar Ranibizumab) in Wet Age- Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Retrospective Pooled Analysis. International Journal of Ophthalmology & Eye Science (IJOES). 2018;6(4):377-383.
  32. Sharma A, Arunaprakash J, Das A, Nayaka A, Kumar N, Parachuri N, et al. Ranizurel safety evaluation in real-world -(RaSER) study. American Journal of Ophthalmology Case Reports. 2022;25:101358.
  33. Committee for Medicinal Products for Human Use (CHMP). Assessment Report - Byooviz (International non-proprietary name: ranibizumab). 24 June 2021 2021. Available at: https://www.ema.europa.eu/en/documents/assessment-report/byooviz-epar-public-assessment-report_en.pdf. Accessed 13 May 2022.
  34. Genentech. Avastin (bevacizumab) - Label (US). US Food and Drug Administration,Last updated October 2021 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s000lbl.pdf. Accessed 16 May 2022.
  35. Roche Registration GmbH. Avastin (bevacizumab) - Summary of product characteristics. European Medicines AgencyLast updated March 2022 2009. Available at: https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Accessed 16 May 2022.
  36. American Academy of Ophthalmology Academy Board of Trustees. The Use of Biosimilars in Ophthalmic Practice - 2022. January 2022 2022. Available at: https://www.aao.org/clinical-statement/use-of-biosimilars-in-ophthalmic-practice. Accessed 21 April 2022.
  37. BioSpace. Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review. https://www.biospace.com/article/releases/coherus-announces-bla-filing-for-lucentis-ranibizumab-biosimilar-candidate-accepted-by-fda-for-review/. Accessed 13 May 2022.
  38. European Medicines Agency. Applications for new human medicines under evaluation by the CHMP: April 2022. https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation. Accessed 13 May 2022.
  39. Holz FG, Minnella AM, Tuli R, Yoganathan P, Parikh S, Hamilton R. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study. PLoS One. 2020;15(12):e0244183.
  40. VanderBeek BL, Scavelli K, Yu Y. Determinants in Initial Treatment Choice for Diabetic Macular Edema. Ophthalmology Retina. 2020;4(1):41-48.
  41. Kelkar A, Webers C, Shetty R, Kelkar J, Labhsetwar N, Pandit A, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian Journal of Ophthalmology. 2020;68(10).
  42. Jackson S, Stokes JP. Impact of out-of-pocket costs on patient initiation, adherence and persistence rates for patients treated with anti-vascular endothelial growth factor medicines. Clin Exp Ophthalmol. 2020;48(4):477-485.
  43. Monés J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. Ophthalmologica. 2020;243(1):1-8.
  44. Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012;153(4):678-686, 686.e671-672.
  45. Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration. Retina. 2012;32(7):1260-1264.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: